Hepcasia Administrator

03

Aug2017

Asia Pacific Situational Updates on Generic DAAs – June 2017

0  
Ever since generic DAA made available in early 2015 with Gilead's VL to several Indian generic manufacturers, there has been some progress as well as challenges in the context of access to Hepatitis C treatment. During Asia Pacific AIDS and Co-infection conference in Hong Kong June 2017, Giten Khwahirakpam from ... Read More

15

Feb2017

Flawed patents on hepatitis C drugs latest to be challenged in global push for access

0  
A joint press release between I-MAK, DNP+ and MSF Access Campaign on challenges to patents (patent oppositions) was filed in India on key hep C drugs sofosbuvir, daclatasvir and velpatasvir. New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat ... Read More
February 15, 2017Hepcasia Administrator

21

Dec2016

Response from CEO, CHAI about the Quick Start program in November 2016

0  
Please click here
December 21, 2016Hepcasia Administrator

21

Dec2016

Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016

0  
Please click here
December 21, 2016Hepcasia Administrator

28

Jun2016

The use of generic DAAs for hepatitis C treatment, Freeman et al 2016

0  
Download PDF

15

Jun2016

Factsheet on updated WHO guidelines for the screening, care and treatment of persons with hepatitis C infection from TREAT Asia/amfAR

0  
Download PDF

03

May2016

Pricing and availability of generic Indian Ledipasvir and Sofosbuvir co-formulation as on 26 April 2016

0  
Download PDF

18

Apr2016

Updated WHO screening, care and treatment of persons with hepatitis C infection_ April 2016.

0  
Download PDF